Moderna improves forecast for 2022 sales from COVID-19 vaccine (updated)

Booster

10/01/2022 12:55

(Adds details on Moderna's booster program for Omicron)
    Jan 10 (Reuters) - Moderna Inc  MRNA.O  said on Monday it
expected to record sales of about $18.5 billion in 2022 from
contracts for its COVID-19 vaccine, and about $3.5 billion from
potential additional purchases including booster candidates
updated for variants.
    The company in November said its sales could be in the range
of $17 billion to $22 billion in 2022.  urn:newsml:reuters.com:*:nL4N2RV2HR
    Moderna said it was in active discussions for additional
COVID-19 vaccine contracts this year.
    The company also said it was developing a booster vaccine
candidate, called mRNA-1273.529, that targets the fast-spreading
Omicron variant and expects it to advance into clinical trials
in early 2022.
     Booster doses of the company's current COVID-19 vaccine,
mRNA-1273, increased neutralizing antibody levels against
Omicron at both 50 microgram and 100 microgram dose levels, the
drugmaker said.
    

 (Reporting by Manojna Maddipatla in Bengaluru; Editing by
Shinjini Ganguli)
 ((manojna.kalyani@thomsonreuters.com; +91  8061822700;))